Trial Profile

A global, Phase 3 post-marketing commitment study of omadacycline for Patients with Moderate to Severe Community-Acquired Bacterial Pneumonia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 24 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Omadacycline (Primary) ; Omadacycline (Primary) ; Moxifloxacin; Moxifloxacin
Indications Bacterial infections; Community-acquired pneumonia
Focus Registrational; Therapeutic Use
Acronyms OPTIC-2
Sponsors Paratek Pharmaceuticals

Most Recent Events

24 Jul 2024 New trial record
18 Jul 2024 According to a Paratek Pharmaceuticals media release, results of this study will be submitted for publication and for presentation at an upcoming scientific congress.
18 Jul 2024 Primary endpoint (non-inferiority (NI) in the intent-to-treat (ITT) population compared to moxifloxacin) has been met, according to a Paratek Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com